|
|
|
|
|
||||||||||||
|
|
|
|
|
|
|
|
价值评估 |
盈利(现时/预测)
-2.21/-1.94
|
企业价值
2.74B
|
资产负债 |
每股账面净值
3.54
|
现金流量 |
现金流量率
--
|
损益表 |
收益
0
|
每股收益
0.14
|
同行比较
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
报价延迟最少15分钟:2025/01/11 11:27 EST
同行比较之报价最少15分钟延迟
业务概览
|
|||
NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments. |